BRAF and neoplasm: Additionally, ex vivo experiments on the tumor cells harvested from the mice demonstrated a significantly reduced spheroid-forming ability in the Antrocin-treated group, accompanied by a decreased expression of the BRAF/MEK/PI3K oncogenic signature, FAP (CAF marker), CD206 (M2 TAM marker), and the stemness marker CD44.